2024
Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).
Erickson B, Enserro D, Lankes H, Dockery L, ghamande S, Oliver M, Gressel G, Castellano T, Ratner E, Deery A, Bishop E, Bradford L, Thomes Pepin J, Burton E, Blank S, Santin A, Havrilesky L, Aghajanian C, Nickles Fader A, Powell M. Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Journal Of Clinical Oncology 2024, 42: tps5641-tps5641. DOI: 10.1200/jco.2024.42.16_suppl.tps5641.Peer-Reviewed Original ResearchUterine serous carcinomaSerous carcinomaMaintenance trastuzumabDual anti-HER2 therapyRecurrent uterine serous carcinomaCombination of pertuzumabAnti-HER2 therapyEfficacy of trastuzumabPhase II portionPhase II/III studiesPhase III studyNext generation sequencing testsEndometrial serous carcinomaFixed dose combinationInterstitial lung diseasePhase II resultsPhase II componentSevere heart diseasePhase II dataVaginal brachytherapyUterine carcinosarcomaPartial responseMaintenance therapyIII studiesOverexpress HER2
2022
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin A, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter A, Childs B, Elbi C, Bulat I. Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal Of Gynecological Cancer 2022, 33: ijgc-2022-003927. PMID: 36564099, PMCID: PMC10086500, DOI: 10.1136/ijgc-2022-003927.Peer-Reviewed Original ResearchConceptsPlatinum-resistant ovarian cancerProgression-free survivalMedian progression-free survivalAnetumab ravtansineObjective response rateOvarian cancerLiposomal doxorubicinMedian durationAdverse eventsDose escalationMesothelin expressionCommon treatment-emergent adverse eventsPlatinum-resistant epithelial ovarian cancerResponse rateAnti-mesothelin monoclonal antibodyTreatment-emergent adverse eventsHigh mesothelin expressionPegylated-liposomal doxorubicinPhase Ib studyPhase III studyDose-limiting toxicityPromising clinical activityEpithelial ovarian cancerAnti-tumor activityCentral immunohistochemistry
2020
372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Santin A, Vergote I, Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland L, Monk B, Coleman R, Herzog T, Siegel J, Walter A, Childs B, Elbi C, Bulat I. 372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. International Journal Of Gynecological Cancer 2020, 30: a154-a154. DOI: 10.1136/ijgc-2020-igcs.322.Peer-Reviewed Original ResearchPlatinum-resistant ovarian cancerProgression-free survivalObjective response rateMedian progression-free survivalPLD combinationAdverse eventsMesothelin expressionClinical activityAnti-mesothelin monoclonal antibodyHigh mesothelin expressionObserved clinical activityPegylated-liposomal doxorubicinSafety/tolerabilityPrimary peritoneal cancerPhase III studyHigh medical needAnetumab ravtansineCentral immunohistochemistryEvaluable patientsExploratory subsetPeritoneal cancerIII studyMedian durationPartial responsePrior lines